Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $30.13, up 1.14%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TEVA shares have gain 6.35% over the last week, with a monthly amount glided 17.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $35. Previously, Scotiabank started tracking the stock with Sector Outperform rating on December 05, 2025, and set its price target to $35. On June 06, 2025, Goldman initiated with a Buy rating and assigned a price target of $24 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $25 on May 28, 2025. JP Morgan upgraded its rating to an Overweight but $23 remained the price target by the analyst firm on May 12, 2025. Argus upgraded its rating to Buy for this stock on July 10, 2024, but kept the price target unchanged to $20. In a note dated March 08, 2024, JP Morgan upgraded a Neutral rating on this stock but restated the target price of $14.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $12.47 and $30.20 over the past year. Currently, Wall Street analysts expect the stock to reach $32.67 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $30.13 at the most recent close of the market. An investor can expect a potential return of 8.43% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.86B for the trailing twelve months, which represents a growth of 3.17%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at -0.0%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.03 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.74 points at the first support level, and at 29.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.48, and for the 2nd resistance point, it is at 30.83.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 1.11. Also, the Quick Ratio is 0.82, while the Cash Ratio stands at 0.18. Considering the valuation of this stock, the price to sales ratio is 2.05, the price to book ratio is 4.77 and price to earnings (TTM) ratio is 49.21.
Transactions by insiders
Recent insider trading involved Bridger Management, LLC (1), Shareholder, that happened on Dec 12 ’25 when 0.15 million shares were purchased. Exec. VP, European Commercial, Daniell Richard completed a deal on Dec 09 ’25 to sell 0.12 million shares. Meanwhile, See “Remarks” Sabag Mark sold 0.22 million shares on Dec 09 ’25.
